Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Pharmacol Drug Dev ; 6(6): 570-576, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28052588

ABSTRACT

This phase 1, randomized, open-label study assessed the absolute bioavailability and pharmacokinetic comparability of sirukumab, a human anti-interleukin-6 monoclonal antibody, following subcutaneous (SC) administration via Prefilled Syringe-UltraSafe Passive® Delivery System (PFS-U) or Prefilled Syringe-SmartJect® Autoinjector (PFS-AI; Janssen Research & Development, LLC, Spring House, Pennsylvania). A total of 144 healthy male subjects were randomized to 5 single-dose treatment groups: sirukumab 50 mg and 100 mg (each by PFS-U and PFS-AI) and sirukumab 100 mg intravenous (IV) infusion. Pharmacokinetic parameters were calculated using noncompartmental analysis. Following SC administration, maximum serum concentrations (Cmax ) and area under the concentration-vs-time curve (AUC) increased in an approximately dose-proportional manner. Median time to reach Cmax was 5 days, and mean half-life ranged from 16 to 19 days. Mean absolute bioavailability of sirukumab by PFS-AI and PFS-U, respectively, was estimated at 92.4% and 81.4% with 100 mg and 88.4% and 94.7% with 50 mg. Ratios of geometric means (90% confidence intervals) of Cmax and AUC0-77d for PFS-AI:PFS-U were 1.13 (1.03, 1.25) and 1.14 (1.05, 1.24), respectively, indicating comparable systemic exposures of sirukumab following a single 100-mg SC dose by PFS-U or PFS-AI. The incidence of antibodies to sirukumab was low (1.4%). No new safety concerns associated with sirukumab were identified at either dose.


Subject(s)
Antibodies, Monoclonal/administration & dosage , Drug Delivery Systems , Interleukin-6/antagonists & inhibitors , Syringes , Adult , Antibodies, Monoclonal/pharmacokinetics , Antibodies, Monoclonal, Humanized , Area Under Curve , Biological Availability , Dose-Response Relationship, Drug , Follow-Up Studies , Half-Life , Humans , Infusions, Intravenous , Injections, Subcutaneous , Male , Middle Aged , Time Factors , Young Adult
2.
J Clin Pharmacol ; 46(4): 456-60, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16554454

ABSTRACT

Hexaminolevulinate (HAL) is a diagnostic agent that allows the visualization of tumor tissue in the bladder by fluorescence cystoscopy. It is administered intravesically via a catheter for 1 hour, followed by blue light bladder inspection to induce selective red tumor fluorescence. Hexaminolevulinate should ideally be confined to the bladder only, but it is likely that some absorption occurs during administration, and therefore the systemic bioavailability is of interest. The bioavailability of HAL was determined by intravesical and intravenous administration of [14C]-HAL hydrochloride to 8 human volunteers. To reduce the radiation dose as low as possible, the ultrasensitive analytical technique of accelerator mass spectrometry was used to measure [14C]-HAL. The bioavailability of [14C]-HAL after intravesical and intravenous administration was determined from the respective area under the curve based on total radioactivity and was determined to be 7% (range, 5%-10%; 90% confidence interval). The systemic absorption of [14C]-HAL after intravesical administration is low and supports previous clinical experience with HAL showing no systemic side effects.


Subject(s)
Aminolevulinic Acid/analogs & derivatives , Photosensitizing Agents/pharmacokinetics , Administration, Intravesical , Adolescent , Adult , Aminolevulinic Acid/administration & dosage , Aminolevulinic Acid/blood , Aminolevulinic Acid/pharmacokinetics , Area Under Curve , Biological Availability , Carbon Radioisotopes , Cross-Over Studies , Half-Life , Humans , Male , Mass Spectrometry , Middle Aged , Photosensitizing Agents/administration & dosage , Photosensitizing Agents/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...